Esperion Therapeutis.Inc. buy Global_Player
Summary
This prediction ended on 01.03.25 with a price of €1.70. With a performance of 6.89%, the BUY prediction by Global_Player for Esperion Therapeutis.Inc. closed with a slight gain. Global_Player has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 3.977% | 3.977% | 77.068% |
| iShares Core DAX® | 0,30 % | 4,70 % | 4,54 % |
| iShares Nasdaq 100 | 0,43 % | 12,26 % | 31,98 % |
| iShares Nikkei 225® | 1,63 % | 12,62 % | 43,26 % |
| iShares S&P 500 | 0,57 % | 7,79 % | 23,48 % |
According to Global_Player what are the pros and cons of Esperion Therapeutis.Inc. for the foreseeable future?
Pros
Cons
Comments by Global_Player for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Global_Player for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
29.08.25
29.08.26
15.09.25
Esperion Therapeutis.Inc.
25.04.24
25.04.25
27.04.24
Esperion Therapeutis.Inc.
28.08.23
28.08.24
30.08.23
Esperion Therapeutis.Inc.
07.12.22
07.12.23
11.12.22
Esperion Therapeutis.Inc.
26.07.21
26.07.22
08.08.21


